Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 1/20 | 0.38 |
| ▸ | ACVR1 | Q04771 | 13/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 12/20 | 0.38 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.37 |
| ▸ | NEK2 | P51955 | 1/20 | 0.37 |
| ▸ | GAK | O14976 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.36 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.36 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.36 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5203198 | 0.99 | FYN (0.38) | FYNACVR1TGFBR1ACVR1BNEK2 | |
| SCHEMBL5209830 | 0.81 | TGFBR1 (0.52) | FYNACVR1TGFBR1ACVR1BKCNH2 | |
| SCHEMBL5207666 | 0.78 | TGFBR1 (0.49) | FYNACVR1TGFBR1ACVR1BKCNH2 | |
| SCHEMBL5205444 | 0.76 | TGFBR1 (0.47) | FYNACVR1TGFBR1ACVR1BNEK2 | |
| SCHEMBL5208695 | 0.75 | ACVR1 (0.53) | FYNACVR1TGFBR1ACVR1BKCNH2 | |
| Hydrochloric Acid SCHEMBL5210606 | 0.74 | ACVR1 (0.52) | FYNACVR1TGFBR1ACVR1BKCNH2 | |
| SCHEMBL5203572 | 0.74 | TGFBR1 (0.52) | FYNACVR1TGFBR1ACVR1BNEK2 | |
| SCHEMBL5208583 | 0.71 | TGFBR1 (0.49) | FYNACVR1TGFBR1ACVR1BKCNH2 | |
| SCHEMBL5205953 | 0.69 | TGFBR1 (0.48) | FYNACVR1TGFBR1ACVR1BNEK2 | |
| SCHEMBL5683636 | 0.66 | TGFBR1 (0.55) | ACVR1TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1403251-B1 | BIS(2-ARYL-5-PYRIDYL) DERIVATIVE | KOWA CO (JP) | 2007-07-18 | — | — | EP | disclosed |
| US-6890940-B2 | Bis(2-aryl-5-pyridyl) derivatives | KOWA CO., LTD. (JP) | 2005-05-10 | — | — | US | disclosed |
| EP-1403251-A1 | BIS(2-ARYL-5-PYRIDYL) DERIVATIVE | Kowa Co., Ltd. (JP) | 2004-03-31 | — | — | EP | disclosed |
| US-20030022886-A1 | Immoglobulin E (IgE) antibody production inhibitor; treating allergic immune diseases such as asthma, dermatitis, inflammatory bowel disease and allergic opthalmopathy | KOWA CO., LTD. (JP) | 2003-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030022886-A1 | Immoglobulin E (IgE) antibody production inhibitor; treating allergic immune diseases such as asthma, dermatitis, inflammatory bowel disease and allergic opthalmopathy | IGLV6-57, IL5, IGSF11 | FYN 1448/4885ACVR1 311/4885TGFBR1 237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.